Cargando…

Expression of BAFF and BR3 in patients with systemic lupus erythematosus

The objective of this study was to examine the relationship between the expression of B cell activating factor (BAFF) and BAFF receptor in patients with disease activity of systemic lupus erythematosus (SLE). Real-time RT-PCR was used to examine BAFF mRNA expression in peripheral blood monocytes of...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, J.H., Jiang, Y., Mu, H., Tang, Z.Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Divulgação Científica 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763815/
https://www.ncbi.nlm.nih.gov/pubmed/26840704
http://dx.doi.org/10.1590/1414-431X20154853
_version_ 1782417321167421440
author Duan, J.H.
Jiang, Y.
Mu, H.
Tang, Z.Q.
author_facet Duan, J.H.
Jiang, Y.
Mu, H.
Tang, Z.Q.
author_sort Duan, J.H.
collection PubMed
description The objective of this study was to examine the relationship between the expression of B cell activating factor (BAFF) and BAFF receptor in patients with disease activity of systemic lupus erythematosus (SLE). Real-time RT-PCR was used to examine BAFF mRNA expression in peripheral blood monocytes of active and stable SLE patients and healthy controls. The percentage of BAFF receptor 3 (BR3) on B lymphocytes was measured by flow cytometry. Soluble BAFF levels in serum were assayed by ELISA. Microalbumin levels were assayed by an automatic immune analysis machine. BAFF mRNA and soluble BAFF levels were highest in the active SLE group, followed by the stable SLE group, and controls (P<0.01). The percentage of BR3 on B lymphocytes was downregulated in the active SLE group compared with the stable SLE group and controls (P<0.01). BAFF mRNA levels and soluble BAFF levels were higher in patients who were positive for proteinuria than in those who were negative (P<0.01). The percentage of BR3 on B lymphocytes was lower in patients who were positive for proteinuria than in those who were negative (P<0.01). The BAFF/BR3 axis may be over-activated in SLE patients. BAFF and BR3 levels may be useful parameters for evaluating treatment.
format Online
Article
Text
id pubmed-4763815
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Associação Brasileira de Divulgação Científica
record_format MEDLINE/PubMed
spelling pubmed-47638152016-03-07 Expression of BAFF and BR3 in patients with systemic lupus erythematosus Duan, J.H. Jiang, Y. Mu, H. Tang, Z.Q. Braz J Med Biol Res Clinical Investigation The objective of this study was to examine the relationship between the expression of B cell activating factor (BAFF) and BAFF receptor in patients with disease activity of systemic lupus erythematosus (SLE). Real-time RT-PCR was used to examine BAFF mRNA expression in peripheral blood monocytes of active and stable SLE patients and healthy controls. The percentage of BAFF receptor 3 (BR3) on B lymphocytes was measured by flow cytometry. Soluble BAFF levels in serum were assayed by ELISA. Microalbumin levels were assayed by an automatic immune analysis machine. BAFF mRNA and soluble BAFF levels were highest in the active SLE group, followed by the stable SLE group, and controls (P<0.01). The percentage of BR3 on B lymphocytes was downregulated in the active SLE group compared with the stable SLE group and controls (P<0.01). BAFF mRNA levels and soluble BAFF levels were higher in patients who were positive for proteinuria than in those who were negative (P<0.01). The percentage of BR3 on B lymphocytes was lower in patients who were positive for proteinuria than in those who were negative (P<0.01). The BAFF/BR3 axis may be over-activated in SLE patients. BAFF and BR3 levels may be useful parameters for evaluating treatment. Associação Brasileira de Divulgação Científica 2016-02-02 /pmc/articles/PMC4763815/ /pubmed/26840704 http://dx.doi.org/10.1590/1414-431X20154853 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Investigation
Duan, J.H.
Jiang, Y.
Mu, H.
Tang, Z.Q.
Expression of BAFF and BR3 in patients with systemic lupus erythematosus
title Expression of BAFF and BR3 in patients with systemic lupus erythematosus
title_full Expression of BAFF and BR3 in patients with systemic lupus erythematosus
title_fullStr Expression of BAFF and BR3 in patients with systemic lupus erythematosus
title_full_unstemmed Expression of BAFF and BR3 in patients with systemic lupus erythematosus
title_short Expression of BAFF and BR3 in patients with systemic lupus erythematosus
title_sort expression of baff and br3 in patients with systemic lupus erythematosus
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763815/
https://www.ncbi.nlm.nih.gov/pubmed/26840704
http://dx.doi.org/10.1590/1414-431X20154853
work_keys_str_mv AT duanjh expressionofbaffandbr3inpatientswithsystemiclupuserythematosus
AT jiangy expressionofbaffandbr3inpatientswithsystemiclupuserythematosus
AT muh expressionofbaffandbr3inpatientswithsystemiclupuserythematosus
AT tangzq expressionofbaffandbr3inpatientswithsystemiclupuserythematosus